• Age: 18 years to 75 years;

• Histologically diagnosed as primary/relapsed/metastasized melanoma;

• Expected life-span more than 3 months;

• Karnofsky≥60% or ECOG score 0-2;

• Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available.

• Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated;

• At least 1 evaluable tumor lesion;

• Hematology and Chemistry（within 7 days prior to enrollment）:

‣ Absolute count of white blood cells≥2.5×10\^9/L;

⁃ Absolute count of neutropils≥1.5×10\^9/L;

⁃ Absolute count of lymphocytes ≥0.7×109/L；

⁃ Platelet count≥100×10\^9；

⁃ hemoglobin≥90 g/L;

⁃ Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);

⁃ International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days);

⁃ Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min;

⁃ Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN);

⁃ Totol bilirubin≤1.5×ULN;

• no absolute or relative contraindications to operation or biopsy;

⁃ Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 1 year after the completion of lymphodepletion；

⁃ Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy and biologics must cease 28 days before obtaining TILs;

⁃ Be able to understand and sign the informed consent document;

⁃ Be able to stick to follow-up visit plan and other requirements in the agreement.